The state of the art of bispecific antibodies for treating human malignancies
Shuhang Wang, Kun Chen, Qi Lei, Peiwen Ma, Andy Q. Yuan, Yong Zhao, Youwei Jiang, Fang Hong, Shujun Xing, Yuan Fang, Ning Jiang, Huilei Miao, Minghui Zhang, Shujun Sun, Zicheng Yu, Wei Tao, Qi Zhu, Yingjie Nie, Ning Li
Abstract
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.